Literature DB >> 24514954

PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients.

Shenyou Sun1, Xiaochun Fei, Yan Mao, Xiumin Wang, David H Garfield, Ou Huang, Jinglong Wang, Fei Yuan, Long Sun, Qixiang Yu, Xiaolong Jin, Jianhua Wang, Kunwei Shen.   

Abstract

The programmed death-1 (PD-1) molecule is mainly expressed on functionally "exhausted" CD8(+) T cells, dampening the host antitumor immune response. We evaluated the ratio between effective and regulatory T cells (Tregs) and PD-1 expression as a prognostic factor for operable breast cancer patients. A series of 218 newly diagnosed invasive breast cancer patients who had undergone primary surgery at Ruijin Hospital were identified. The influence of CD8(+) cytotoxic T lymphocytes, FOXP3(+) (Treg cell marker), and PD-1(+) immune cell counts on prognosis was analyzed utilizing immunohistochemistry. Both PD-1(+) immune cells and FOXP3(+) Tregs counts were significantly associated with unfavorable prognostic factors. In bivariate, but not multivariate analysis, high tumor infiltrating PD-1(+) cell counts correlated with significantly shorter patient survival. Our results suggest a prognostic value of the PD-1(+) immune cell population in such breast cancer patients. Targeting the PD-1 pathway may be a feasible approach to treating patients with breast cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24514954     DOI: 10.1007/s00262-014-1519-x

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  67 in total

Review 1.  A review of the importance of immune responses in luminal B breast cancer.

Authors:  Delia J Nelson; Briony Clark; Kylie Munyard; Vincent Williams; David Groth; Jespal Gill; Henry Preston; Arlene Chan
Journal:  Oncoimmunology       Date:  2017-01-19       Impact factor: 8.110

2.  Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.

Authors:  Arutselvan Natarajan; Aaron T Mayer; Robert E Reeves; Claude M Nagamine; Sanjiv Sam Gambhir
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

3.  Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer.

Authors:  Dhifaf Sarhan; Caroline Leijonhufvud; Shannon Murray; Kristina Witt; Christina Seitz; Majken Wallerius; Hanjing Xie; Anders Ullén; Ulrika Harmenberg; Elisabet Lidbrink; Charlotte Rolny; John Andersson; Andreas Lundqvist
Journal:  Oncoimmunology       Date:  2017-06-14       Impact factor: 8.110

Review 4.  Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.

Authors:  Kim C Ohaegbulam; Amer Assal; Eszter Lazar-Molnar; Yu Yao; Xingxing Zang
Journal:  Trends Mol Med       Date:  2014-10-30       Impact factor: 11.951

5.  Synthetic Matrix Scaffolds Engineer the In Vivo Tumor Immune Microenvironment for Immunotherapy Screening.

Authors:  Meghan J O'Melia; Adriana Mulero-Russe; Jihoon Kim; Alyssa Pybus; Deborah DeRyckere; Levi Wood; Douglas K Graham; Edward Botchwey; Andrés J García; Susan N Thomas
Journal:  Adv Mater       Date:  2022-01-31       Impact factor: 30.849

6.  Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection.

Authors:  Shohei Eto; Kozo Yoshikawa; Masaaki Nishi; Jun Higashijima; Takuya Tokunaga; Toshihiro Nakao; Hideya Kashihara; Chie Takasu; Takashi Iwata; Mitsuo Shimada
Journal:  Gastric Cancer       Date:  2015-07-26       Impact factor: 7.370

7.  Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma.

Authors:  Yuichi Imai; Kosei Hasegawa; Hirokazu Matsushita; Nao Fujieda; Sho Sato; Etsuko Miyagi; Kazuhiro Kakimi; Keiichi Fujiwara
Journal:  Oncol Lett       Date:  2018-02-21       Impact factor: 2.967

8.  Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.

Authors:  Krzysztof M Zak; Radoslaw Kitel; Sara Przetocka; Przemyslaw Golik; Katarzyna Guzik; Bogdan Musielak; Alexander Dömling; Grzegorz Dubin; Tad A Holak
Journal:  Structure       Date:  2015-10-22       Impact factor: 5.006

9.  Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis.

Authors:  Ramy R Saleh; Jordan L Scott; Nicholas Meti; Danielle Perlon; Rouhi Fazelzad; Alberto Ocana; Eitan Amir
Journal:  Mol Diagn Ther       Date:  2022-02-01       Impact factor: 4.074

Review 10.  Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.

Authors:  Mengling Wu; Qianrui Huang; Yao Xie; Xuyi Wu; Hongbo Ma; Yiwen Zhang; Yong Xia
Journal:  J Hematol Oncol       Date:  2022-03-12       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.